The emerging role of miR-506 in cancer

Jian Li; Jingfang Ju; Bing Ni; Huaizhi Wang

doi:10.18632/oncotarget.11294

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The emerging role of miR-506 in cancer

Jian Li, Jingfang Ju, Bing Ni and Huaizhi Wang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:62778-62788. https://doi.org/10.18632/oncotarget.11294

Metrics: PDF 2197 views | HTML 3557 views | ?

Abstract

Jian Li1, Jingfang Ju2, Bing Ni3 and Huaizhi Wang1

1 Institute of Hepatopancreatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, PR China

2 Translational Research Laboratory, Department of Pathology, Stony Brook University, Stony Brook, NY, USA

3 Department of Pathophysiology and High Altitude Pathology, Third Military Medical University, Chongqing, PR China

Correspondence to:

Huaizhi Wang, email:

Bing Ni, email:

Jingfang Ju, email:

Keywords: microRNAs; miR-506; cancer; tumor suppressor

Received: April 06, 2016 Accepted: August 10, 2016 Published: August 15, 2016

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression. They are involved in almost all biological processes, and many have been identified as potential oncogenes or tumor suppressor genes. miR-506 was recently discovered to play pivotal roles in regulating cell proliferation, differentiation, migration and invasion. Dysregulation of miR-506 has been demonstrated in multiple types of cancers; however, whether it functions as an oncogene or a tumor suppressor seems to be context-dependent. Altered miR-506 expression in cancer is caused by promoter methylation and changes in upstream transcription factors. In this review, we summarize the current understanding of the diverse roles and underlying mechanisms of miR-506 and its involvement in cancer, and suggest the potential therapeutic strategy based on miR-506.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11294

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

The emerging role of miR-506 in cancer

Abstract